Cefminox
Chemical compound
- J01DC12 (WHO)
- In general: ℞ (Prescription only)
- (6R,7S)-7-(((((2S)-2-amino-2-carboxyethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
- 84305-41-9 Y
- 71141
- 64286 N
- PW08Y13465
- D07642 Y
- CHEBI:135817
- ChEMBL1276342 N
- Interactive image
- O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)CSC[C@H](C(=O)O)N)CSc3nnnn3C)C(=O)O
InChI
- InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1 N
- Key:JSDXOWVAHXDYCU-VXSYNFHWSA-N N
Cefminox (INN) is a second-generation cephalosporin antibiotic.[1][2]
Spectrum
Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. [citation needed]The following represents MIC data for a few medically significant microorganisms.
- Clostridium difficile: 2 - 4 μg/ml
- Escherichia coli: 0.125 - 16 μg/ml
- Pseudomonas aeruginosa: 256 μg/ml[3]
References
- ^ Torres AJ, Valladares LD, Jover JM, Sánchez-Pernaute A, Frías J, Carcas AJ, et al. (September 2000). "Cefminox versus metronidazole plus gentamicin intra-abdominal infections: a prospective randomized controlled clinical trial". Infection. 28 (5): 318–22. doi:10.1007/s150100070027. PMID 11073141. S2CID 41555982.
- ^ US 8497086, "Reaction Medium For Methicillin-Resistant Staphylococcus Aureus (MRSA) Bacteria", issued 20 July 2013, assigned to Biomereux
- ^ "Cefminox sodium Susceptibility and Minimum Inhibitory Concentration (MIC) Data" (PDF). www.toku-e.com.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Glycopeptides Lipoglycopeptides |
|
---|---|
Lipopeptides |
|
Polymyxins |
|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e